Dialysis world news


Nxstage Medical, Inc. (NXTM) Discloses Form 4 Insider Selling : Exec. Jeffrey ... - OTC Outlook

Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Jeffrey H Burbank , Chief Executive Officer of Nxstage Medical, Inc. sold 20,000 shares on Jun 17, 2015. The Insider selling transaction was disclosed on Jun 19, 2015 to the Securities and Exchange Commission. The shares were sold at $15.56 per share for a total value of $311,200.00 according to InsiderTradingReport.

12.08% of the shares are held by the company Insiders, 91.2% of the shares are held by the institutions. Company shares has an average 3 month share volume of 477,362 and an average 10 day volume is recorded to be 425,475 The Company has disclosed insider buying and selling activities to the Securities Exchange,The (President) of Nxstage Medical, Inc., Turk Joseph E Jr sold 2,839 shares at $16 on June 10, 2015. The Insider selling transaction had a total value worth of $45,424. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. NxStage Medical, Inc. (NASDAQ:NXTM) witnessed a volatile trading activity on Friday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $15.75 and reached the intraday high at $15.9. The bulls started the profit booking and pushed the shares to intraday low of $15.67. The trading session was marked by a volume range of 569,907 shares exchanging hands. The 52-week high of the shares is $19.63 and the 52-week low is $11.5. The market cap of the company stands at $993 million and there are 63,238,000 shares in public circulation. The shares of NXTM have rallied 12.35% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $16.9 and the 200 day moving average is recorded at $17.56. S&P 500 has rallied 8.07% during the last 52-weeks. Several Brokerage firms have commented on company shares. In a research note released to the investors, Canaccord Genuity maintains its rating on NxStage Medical, Inc. (NASDAQ:NXTM).The analysts at the brokerage house have a current rating of Buy on the counter. In a recent information released to the investors, Canaccord Genuity raises the new price target from $24 per share to $27 per share. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

...

 
Company Shares of Rockwell Medical, Inc. Rally 5.86% - American Trade Journal

Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) rose by 5.86% in the past week and 34.16% for the last 4 weeks. In the past week, the shares has outperformed the S&P 500 by 5.06% and the outperformance increases to 35.18% for the last 4 weeks. For the current week, the company shares have a recommendation consensus of Buy.

18.55% of the shares are held by the company Insiders, 28% of the shares are held by the institutions. Company shares has an average 3 month share volume of 564,811 and an average 10 day volume is recorded to be 898,625 Shares of the company have rallied 22.18% in the past 52 Weeks. On June 16, 2015 The shares registered one year high of $14.95 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $11.32 and the 200 day moving average is recorded at $10.48. S&P 500 has rallied 7.51% during the last 52-weeks. Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) ended Friday session in red amid volatile trading. The shares closed down 0.2 points or 1.4% at $14.1 with 557,110 shares getting traded. Post opening the session at $14.44, the shares hit an intraday low of $13.96 and an intraday high of $14.4484 and the price vacillated in this range throughout the day. The company has a market cap of $707 million and the number of outstanding shares has been calculated to be 50,169,000 shares. The 52-week high of Rockwell Medical, Inc. (NASDAQ:RMTI) is $14.95 and the 52-week low is $8.095. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...

 
Utah inmate's son sues after father misses dialysis, dies - Fox News
ramone661.jpg

This image provided by the Utah Department of Corrections shows inmate Ramon C. Estrada. (AP)

The son of an inmate who died at the Utah state prison has sued corrections officials and health care providers, accusing them of violating his father's civil rights by failing to give him dialysis for two days.

Inmate Ramon C. Estrada died April 5 after two dialysis technicians switched shifts and nobody showed up for his appointment.

Estrada's son, Jose Estrada, who lives in Edcouch, Texas, filed the lawsuit in federal court this week. The lawsuit was filed against the state prison warden, the clinical services director at the prison and the director of the offsite dialysis clinic that's part of the University of Utah health care system

"Defendants exhibited a shocking degree of deliberate indifference and reckless disregard for the serious and evident medical needs of Ramon Estrada," the lawsuit alleges.

Utah Department of Corrections spokeswoman Brooke Adams said she can't comment because they have not officially received the lawsuit and because the department's internal investigation is ongoing.

University of Utah Health Care system spokeswoman Kathy Wilets also declined comment on the lawsuit, referring to statements made in April when the university said it deeply regretted the mistake and vowed to take the necessary steps to ensure a scheduling mix-up would not happen again.

The two technicians have been disciplined, but they remain employees, Wilets said. The health care system's investigation didn't find any bad intentions, just a terrible scheduling error, she said.

Clair Coleman, office manager at the South Valley Dialysis Center where the technicians work, declined comment on a lawsuit he hasn't seen yet. But he said they have taken steps to improve scheduling and ensure prison officials know how to get ahold of him or his workers.

He lamented the fact that prison workers waited two days to call his office after the appointments were missed in April. "All the changes in the world won't make a difference if the prison doesn't call when someone is late or doesn't show up," Coleman said.

The attorney for the Estrada family, Alyson McAllister, said the four adult children are suing because they can't get any information from the prison about what happened and because they want to ensure the same thing doesn't happen to other inmates.

"Those technicians definitely bear some responsibility for this, but more responsibility lies on the supervisors and the jail," McAllister said. "There needs to be some kind of oversight so a simple scheduling error like this doesn't' cause catastrophic damages."

Autopsy results have not yet been released, but corrections officials say it appeared Estrada died of a heart attack related to kidney failure. The lawsuit doesn't mention a heart attack, but it says he died of kidney failure.

Estrada had been in prison since August 2005 on a rape conviction. He was 62 and was set to be paroled less than three weeks later.

The Salt Lake Tribune first reported the lawsuit.

The lawsuit says the prison failed to provide Ramon Estrada with a level of care that a "civilized society would think necessary." It also accuses prison officials of failing to intervene in time to prevent his death.

Six other male inmates were also waiting for dialysis treatment because of the scheduling mix-up and were taken to a hospital for evaluation.

The situation reflects a lack of adequate training and oversight of dialysis providers at the prison, the lawsuit says.

The lawsuit doesn't list a monetary figure for the damages they are seeking, but it says Ramon C. Estrada's death deprived his family of "the companionship and society of their father."

...

 
Regular dialysis: Edhi's hospital visit was a routine check-up, says family - The Express Tribune
PHOTO: AFP

PHOTO: AFP

KARACHI: 

Friends and well-wishers of philanthropist Abdul Sattar Edhi can breathe a sigh of relief as his visit to the hospital on Saturday was just a routine check-up, said his family.

The news of Edhi’s illness and admission at the Sindh Institute of Urology and Transplantation (SIUT) spread on Sunday morning but members of his family said there was nothing to worry about.

Edhi was taken to SIUT but only for his routine dialysis treatment, said hospital sources. He arrived at the facility on Saturday and was admitted on doctor’s advice. “It was a routine check-up and he is absolutely fine,” confirmed Anwar Kazmi, the spokesperson of the Edhi Foundation. He also informed that Edhi has been admitted at the hospital many times in the past.

Published in The Express Tribune, June 22nd, 2015. 

...

 
Additional dialysis centers put up in Davao to serve more patients - BusinessWorld Online Edition
BusinessWorld Online Edition
As a result, the Nephrology Center of St. Alexius (NCSA) has chosen to establish eight dialysis centers in Mindanao -- an investment of P120 million total -- to serve patients whose needs remain unmet despite available facilities in the Southern

...

 
<< Start < Prev 81 82 83 84 85 86 87 88 89 90 Next > End >>

Page 83 of 2630
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.